{"url_path":"/sec/drmaw/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1853816/0001493152-26-022719-index.html","accession_number":"0001493152-26-022719","cik":"0001853816","ticker":"DRMA","issuer_name":"Dermata Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1853816/0001493152-26-022719-index.html","primary_entity_key":"0001853816","primary_entity_name":"Dermata Therapeutics, Inc."},"word_count":57,"has_tables":true,"body_markdown":"**ITEM\n5: OTHER INFORMATION**\n\n \n\n*Rule\n10b5-1 Trading Plans*\n\n \n\nDuring\nthe fiscal quarter ended March 31, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of\nthe Company adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,”\nas each term is defined in Item 408(c) of Regulation S-K.\n\n \n\n32"}